BRIEF—Third Australian indication approved for Orencia

US pharma major Bristol-Myers Squibb has announced that the Australian Therapeutic Goods Administration (TGA) has approved an additional indication for Orencia (abatacept) for active psoriatic arthritis (PsA) in adults when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Orencia, which inhibits T-cell activation via its co-stimulation blockade mechanism to reduce inflammation and treat symptoms of PsA, can be used with or without non-biologic DMARDs.

This approval marks the third autoimmune disease indication for ORENCIA in Australia, including rheumatoid arthritis and juvenile idiopathic arthritis.